Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) Revenue
Annual & quarterly revenue history · segment & region breakdown
ALNY · revenue · updated Jun 10, 2026
Core revenue metrics
Trailing 12 monthsAlnylam Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $4.29B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
Compare revenue vs peers
BiotechnologyCompare ALNY revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Alnylam Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Alnylam Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Alnylam Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ALNY revenue · 4 questionsALNY's trailing twelve-month (TTM) revenue is $4.29B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · Alnylam Pharmaceuticals, Inc. SEC filings · GAAP · Alnylam Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026